Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02101970 · ClinicalTrials.gov registry record · NA

Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women

A NA study, sponsored by Carol Fabian, MD.

Completed
Registry status
NA
Development phase
46
Enrollment target

NCT02101970 is a NA study that has completed, run by Carol Fabian, MD. The registered enrollment target is 46 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02101970, a NA study, has completed, sponsored by Carol Fabian, MD.

COMPLETED
Registry status
NA
Development phase
46 participants
Enrollment target

Study Summary

The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.

Interventions

  • OTHER Placebo Capsule
  • DIETARY_SUPPLEMENT Omega-3 Fatty Acids
  • OTHER Diet and Exercise

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2014-03
Est. Completion 2018-08-27
Phase NA

Sponsor

Carol Fabian, MD

14 total trials

What the Registry Record Tells You About NCT02101970

The ClinicalTrials.gov registry entry for NCT02101970 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carol Fabian, MD, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo Capsule is the first listed.

NCT02101970 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02101970 about?

NCT02101970 is a clinical study titled "Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women". The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when comp...

What is the current status of trial NCT02101970?

This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2014-03. Estimated completion is 2018-08-27.

What interventions are being tested in trial NCT02101970?

The interventions under investigation include: Placebo Capsule (OTHER), Omega-3 Fatty Acids (DIETARY_SUPPLEMENT), Diet and Exercise (OTHER).

Who is sponsoring clinical trial NCT02101970?

This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.